[
    [
        {
            "time": "2018-01-02",
            "original_text": "Lilly Rockets On Alzheimer's News — And 3 Other Highlights From Key Health Care Meeting",
            "features": {
                "keywords": [
                    "Lilly",
                    "Alzheimer's",
                    "Rockets",
                    "Health Care"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly Rockets On Alzheimer's News — And 3 Other Highlights From Key Health Care Meeting",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Eli Lilly, Office Depot, Crocs: 5 Gainers for Monday",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Gainers",
                    "Monday"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "retail",
                    "consumer goods"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly, Office Depot, Crocs: 5 Gainers for Monday",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Here's Why Eli Lilly Broke to the Upside",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Upside"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Here's Why Eli Lilly Broke to the Upside",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Lilly’s Alzheimer's Drug Isn’t Worth $20 Billion Yet",
            "features": {
                "keywords": [
                    "Lilly",
                    "Alzheimer's",
                    "Drug",
                    "Worth"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly’s Alzheimer's Drug Isn’t Worth $20 Billion Yet",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study",
            "features": {
                "keywords": [
                    "Biogen",
                    "stock",
                    "up",
                    "Lilly",
                    "Alzheimer's",
                    "positive data"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Return On Capital Employed Overview: Eli Lilly",
            "features": {
                "keywords": [
                    "Return",
                    "Capital Employed",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Return On Capital Employed Overview: Eli Lilly",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Dow Off Lows as Energy, Healthcare Rise; Democrats Eye Trump Impeachment",
            "features": {
                "keywords": [
                    "Dow",
                    "Energy",
                    "Healthcare",
                    "Rise",
                    "Impeachment"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "energy",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow Off Lows as Energy, Healthcare Rise; Democrats Eye Trump Impeachment",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Eli Lilly Stock Rockets To Record As Alzheimer's Drug Improves Cognition",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock",
                    "Rockets",
                    "Alzheimer's",
                    "Cognition"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Rockets To Record As Alzheimer's Drug Improves Cognition",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Why Eli Lilly Stock Is Crushing It Today",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock",
                    "Crushing"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Why Eli Lilly Stock Is Crushing It Today",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Dow Jones Today, Stocks Slump As Trump Ban Slams Twitter, Lilly Soars On Alzheimer's News, Boeing Slips After 737 Crash",
            "features": {
                "keywords": [
                    "Dow Jones",
                    "Stocks",
                    "Slump",
                    "Trump",
                    "Twitter",
                    "Lilly",
                    "Alzheimer's",
                    "Boeing",
                    "Crash"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "aerospace"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Dow Jones Today, Stocks Slump As Trump Ban Slams Twitter, Lilly Soars On Alzheimer's News, Boeing Slips After 737 Crash",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Eli Lilly Stock Gains as Drug Slows Decline in Alzheimer’s Patients",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock",
                    "Gains",
                    "Drug",
                    "Alzheimer’s",
                    "Patients"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Gains as Drug Slows Decline in Alzheimer’s Patients",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction",
            "features": {
                "keywords": [
                    "FDA",
                    "Jardiance",
                    "New Drug Application",
                    "heart failure"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Lilly's stock jumps 15% after experimental Alzheimer's drug shows it can slow cognitive decline",
            "features": {
                "keywords": [
                    "Lilly",
                    "stock",
                    "jumps",
                    "Alzheimer's",
                    "cognitive decline"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's stock jumps 15% after experimental Alzheimer's drug shows it can slow cognitive decline",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial",
            "features": {
                "keywords": [
                    "Lilly",
                    "Donanemab",
                    "Clinical Decline",
                    "Alzheimer's",
                    "Phase 2 Trial"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]